CORCEPT THERAPEUTICS INC 4

Chief Development Officer William Guyer exercised 16,300 options and sold 16,300 Corcept Therapeutics (CORT) common shares on August 10, 2026 under a 10b5-1 plan, ending with 20,285 shares owned.

On August 10, 2026, Corcept Therapeutics Inc. Chief Development Officer William Guyer exercised 16,300 stock options at an exercise price of $21.65 per share, acquiring 16,300 shares of common stock, and then sold a total of 16,300 shares on the same day in two open-market transactions pursuant to a pre-established Rule 10b5-1 trading plan. The sales consisted of 11,530 shares at a weighted average price of $113.1772 per share and 4,770 shares at a weighted average price of $114.0371 per share, generating aggregate sale proceeds of roughly $1.84 million, while the option exercise cost was approximately $353,000. Following these transactions, Guyer held 20,285 shares of Corcept common stock directly, including 1,599 shares underlying unvested restricted stock awards that will vest in full one year from their respective grant dates, for an estimated post-transaction equity value of about $2.29 million based on the reported sale prices.

Filing Facts

CIK

1088856

Ticker

CORT

Form

4

Source Type

fda

Accession

0001193125-26-346942

Alert Tier

7